Bifunctional Blockade: A Novel Immunotherapy Approach for Cervical Cancer.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 35947045.
- Also identified by DOI 10.1158/1078-0432.CCR-22-1779 and PMC identifier 10018812.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
SHR-1701, a bispecific fusion protein directed against PD-L1 and TGFβ, demonstrates promising clinical activity in advanced/recurrent cervical cancer. A recent study serves as a proof of principle that the TGFβ pathway may be successfully targeted, and that bispecific antibodies offer a novel therapeutic approach to do so. See related article by Feng et al., p. 5297.
Medical subject headings
- Uterine Cervical Neoplasms
- Antibodies, Bispecific